Causaly and Microsoft target one of drug discovery’s most expensive decisions: which target to pursue

At Microsoft Build 2026, the software giant’s annual developer conference, held June 2 and 3 in San Francisco, the life sciences AI company Causaly announced a collaboration with Microsoft aimed at one of drug discovery’s earliest and most consequential decisions: which biological targets are worth pursuing. Causaly runs an agentic AI platform that reads across the external scientific literature and a customer’s internal data, then interprets what it finds through curated biomedical knowledge graphs. It is one of a fast-growing cluster of companies selling AI-enabled scientific evidence tools, lab-data platforms, and agentic R&D workflows. Its claimed edge is that scientists can see the reasoning. “Everything needs to be inspectable,” co-founder and CEO Yiannis Kiachopoulos said. “You don’t want black boxes.”


Read the full announcement on: R&D World